Latest MANE news and sentiment

Veradermics, Incorporated (NYSE:MANE) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $153.00. While the company reported an EPS of -$0.58, insider selling activity, including directors selling 961,000 shares worth $103.1 million, was noted. However, several institutional investors either established or increased their positions in Veradermics during the second quarter.

Published

27 Aug 2026 21:54

Catalyst

Earnings

Coverage

Direct company

Duplicates

1 consolidated

Veradermics, Incorporated (NYSE:MANE) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $153.00. While the company reported an EPS of -$0.58, insider selling activity, including directors selling 961,000 shares worth $103.1 million, was noted. However, several institutional investors either established or increased their positions in Veradermics during the second quarter.

Published

27 Aug 2026 09:41

Catalyst

Earnings

Coverage

Direct company

Duplicates

1 consolidated

Veradermics, Incorporated (NYSE:MANE) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $153.00. While the company reported an EPS of -$0.58, insider selling activity, including directors selling 961,000 shares worth $103.1 million, was noted. However, several institutional investors either established or increased their positions in Veradermics during the second quarter.

Published

27 Aug 2026 08:00

Catalyst

Earnings

Coverage

Direct company

Duplicates

1 consolidated

Published

26 Aug 2026 23:32

Catalyst

Earnings

Coverage

Direct company

Duplicates

1 consolidated

Published

26 Aug 2026 08:00

Catalyst

Earnings

Coverage

Direct company

Duplicates

1 consolidated

Veradermics Inc. stock slid 4.8% due to persistent insider selling pressure, dilution concerns, and a widening Q2 2026 net loss. Multiple insiders, including CEO Reid Alexander Waldman and director-linked entities, sold significant shares, signaling a lack of confidence despite pre-scheduled plans. The company also registered additional shares for potential sale, adding to supply concerns, while broader market weakness offered little support.

Published

25 Aug 2026 09:12

Catalyst

Earnings

Coverage

Direct company

Duplicates

1 consolidated

Veradermics Inc (MANE) shares dropped 4.8% after Montanova Capital, LLC disclosed an insider sale of 750,000 shares of Veradermics common stock on August 19 and 20 at $107.25 per share. Montanova Capital also acquired pre-funded warrants for 300,000 shares on August 20. Entities affiliated with Montanova Capital continue to hold a significant number of shares, with David Friedman, a Managing Director at Montanova Capital, serving on Veradermics’ board of directors.

Published

24 Aug 2026 13:34

Catalyst

Market update

Coverage

Direct company

Duplicates

1 consolidated

VeraDermics, Inc. (MANE) is currently considered a "Hold" despite a recent price decline and oversold RSI, due to its impressive year-to-date growth of +504.82% and positive Phase 2 trial results for VDPHL01. The main concerns are its negative earnings trend and lack of current sales revenue, although its balance sheet shows strong equity. Analysts have issued "Buy" ratings with price targets ranging from $160 to $182, citing the potential of VDPHL01 for hair loss treatment.

Published

23 Aug 2026 11:17

Catalyst

Earnings

Coverage

Direct company

Duplicates

1 consolidated

Veradermics Director Montanova Capital, LLC sold 750,000 shares of the company's stock for over $80 million, significantly reducing its position. Following this sale, Veradermics' shares experienced a 1.9% dip, despite the company meeting analyst earnings estimates for the quarter. Analyst sentiment for MANE remains largely positive, with a consensus "Moderate Buy" rating and an average price target of $153.

Published

22 Aug 2026 00:11

Catalyst

Analyst action

Coverage

Direct company

Duplicates

1 consolidated

Veradermics Director Montanova Capital, LLC sold 750,000 shares of the company's stock for over $80 million, significantly reducing its position. Following this sale, Veradermics' shares experienced a 1.9% dip, despite the company meeting analyst earnings estimates for the quarter. Analyst sentiment for MANE remains largely positive, with a consensus "Moderate Buy" rating and an average price target of $153.

Published

22 Aug 2026 00:10

Catalyst

Analyst action

Coverage

Direct company

Duplicates

1 consolidated

Entities associated with Veradermics (MANE), including Montanova Capital, LLC and Averill funds, reported significant insider trading activity. On August 20, 2026, they exercised 300,000 Pre-Funded Warrants into common stock, and on August 19, 2026, they sold an aggregate of 750,000 common shares at $107.25 per share. All transactions were reported as indirect ownership and the Rule 10b5-1 checkbox was not checked, indicating these were not pre-planned trades.

Published

21 Aug 2026 23:10

Catalyst

Market update

Coverage

Direct company

Duplicates

1 consolidated

Investment entities associated with Montanova Capital, LLC and Aaron Cowen have filed an updated Schedule 13D/A for Veradermics, Inc. (MANE), reporting a beneficial ownership of 8.8% of outstanding shares. This update includes the sale of 750,000 shares at $107.25 each on August 19, 2026, and the exercise of pre-funded warrants for 300,000 shares at $0.00001 per share on August 20, 2026, potentially causing dilution for existing shareholders. The filing details the ownership breakdown among Averill Master Fund, Ltd. and Averill Madison Master Fund, Ltd., and clarifies Montanova Capital's role as investment manager.

Published

21 Aug 2026 23:10

Catalyst

Market update

Coverage

Direct company

Duplicates

1 consolidated

Veradermics Director Montanova Capital, LLC sold 750,000 shares of the company's stock for over $80 million, significantly reducing its position. Following this sale, Veradermics' shares experienced a 1.9% dip, despite the company meeting analyst earnings estimates for the quarter. Analyst sentiment for MANE remains largely positive, with a consensus "Moderate Buy" rating and an average price target of $153.

Published

21 Aug 2026 08:00

Catalyst

Analyst action

Coverage

Direct company

Duplicates

1 consolidated

Veradermics, Inc. (MANE) Chief R&D Officer David Hollander filed an initial statement of beneficial ownership (Form 3) reporting no transactions or beneficial ownership in the company's securities. This filing indicates his entry into the insider ranks without currently holding any shares. The Form 3 serves as an initial inventory sheet for his insider status, allowing future tracking of his holdings.

Published

20 Aug 2026 23:41

Catalyst

Deals and strategy

Coverage

Direct company

Duplicates

1 consolidated

An insider at Veradermics (MANE.US) has filed a Form 144, indicating a proposal to sell 6.37 million common stocks. This filing provides notice of the individual's intent to sell a significant number of shares in the company.

Published

20 Aug 2026 10:41

Catalyst

Market update

Coverage

Direct company

Duplicates

1 consolidated

Averill Master Fund, Ltd., an affiliate of Veradermics, Inc. (MANE), has filed a Rule 144 notice to sell 690,601 shares of common stock through BofA Securities, Inc. on the NYSE. These shares were obtained from the conversion of Series B Preferred Stock, acquired in November 2024 and converted in February 2026. This filing indicates no prior Rule 144 sales by this seller in the last three months.

Published

20 Aug 2026 00:40

Catalyst

Market update

Coverage

Direct company

Duplicates

2 consolidated

Published

19 Aug 2026 16:41

Catalyst

Earnings

Coverage

Direct company

Duplicates

1 consolidated

Published

19 Aug 2026 08:00

Catalyst

Earnings

Coverage

Direct company

Duplicates

1 consolidated

Veradermics CEO Reid Alexander Waldman sold 67,500 shares of the company's stock for approximately $7.28 million, reducing his ownership by 28.32%. The sale was made under a pre-arranged Rule 10b5-1 trading plan. The company's shares rose 2.9% following the news, and analysts maintain a "Moderate Buy" rating with an average price target of $153.

Published

19 Aug 2026 04:42

Catalyst

Earnings

Coverage

Direct company

Duplicates

1 consolidated

Timothy August Durso, an insider at Veradermics (NYSE:MANE), sold 43,500 shares of the company's stock for approximately $4.69 million on August 17th. This transaction, executed under a Rule 10b5-1 plan, reduced his ownership by over 35%. Veradermics shares rose by 2.9% on Tuesday, and the company reported quarterly EPS in line with analyst expectations, while analysts maintain a "Moderate Buy" rating with an average price target of $153.00.

Published

19 Aug 2026 04:42

Catalyst

Analyst action

Coverage

Direct company

Duplicates

1 consolidated

Veradermics CEO Reid Alexander Waldman sold 67,500 shares of the company's stock for approximately $7.28 million, reducing his ownership by 28.32%. The sale was made under a pre-arranged Rule 10b5-1 trading plan. The company's shares rose 2.9% following the news, and analysts maintain a "Moderate Buy" rating with an average price target of $153.

Published

19 Aug 2026 04:13

Catalyst

Earnings

Coverage

Direct company

Duplicates

1 consolidated

Veradermics' Chief Technical Officer, Timothy August Durso, exercised stock options for 3,452 shares and subsequently sold 43,500 common shares in multiple open-market transactions. These sales were conducted under a Rule 10b5-1 trading plan at weighted average prices ranging from $106.71 to $111.28 per share, netting approximately $4.69 million in gross proceeds. After these transactions, Durso holds 78,142 shares of common stock.

Published

19 Aug 2026 02:42

Catalyst

Earnings

Coverage

Direct company

Duplicates

1 consolidated

Veradermics CEO Reid Alexander Waldman sold 67,500 shares of the company's stock for approximately $7.28 million, reducing his ownership by 28.32%. The sale was made under a pre-arranged Rule 10b5-1 trading plan. The company's shares rose 2.9% following the news, and analysts maintain a "Moderate Buy" rating with an average price target of $153.

Published

18 Aug 2026 08:00

Catalyst

Earnings

Coverage

Direct company

Duplicates

1 consolidated

A Veradermics (NYSE: MANE) shareholder has filed a Form 144 notice for the proposed sale of 135,000 common shares, valued at an aggregate market value of $15,022,800. These shares include 3,452 acquired via stock option and 131,548 founder shares. As of August 17, 2026, Veradermics has 41,780,136 shares outstanding on the NYSE, with no reported sales of these specific securities in the past three months.

Published

17 Aug 2026 22:40

Catalyst

Market update

Coverage

Direct company

Duplicates

1 consolidated

Veradermics, Inc. (NYSE: MANE) had an EFFECT filing accepted by the SEC EDGAR on August 17, 2026, with an effectiveness date of August 14, 2026, at 4:00 P.M. The filing was Form S-1. The company's recent news includes financial results, clinical progress updates, and upcoming investor conference presentations.

Published

17 Aug 2026 11:43

Catalyst

Market update

Coverage

Direct company

Duplicates

1 consolidated

Published

17 Aug 2026 09:02

Catalyst

Market update

Coverage

Direct company

Duplicates

1 consolidated

This article analyzes Veradermics' (NYSE:MANE) cash burn rate, concluding that the company has a strong cash runway of many years, backed by US$820m in cash reserves and zero debt as of June 2026. Despite an 86% increase in cash burn over the last year, analysts predict the company will reach free cash flow breakeven before exhausting its funds. The analysis suggests that Veradermics can easily raise additional capital if needed, given its low cash burn relative to its market capitalization.

Published

15 Aug 2026 05:11

Catalyst

Balance sheet

Coverage

Direct company

Duplicates

1 consolidated

SR One-affiliated funds have reduced their stake in Veradermics (MANE) by selling 321,749 common shares at $104.30 per share, totaling approximately $33.5 million. Following this transaction, SR One's combined holdings represent 4.9% of Veradermics' outstanding common stock, bringing their beneficial ownership below the 5% threshold. The funds reported no current plans for control-related actions but may dispose of additional shares based on market conditions.

Published

15 Aug 2026 02:12

Catalyst

Deals and strategy

Coverage

Direct company

Duplicates

1 consolidated

Entities linked to Veradermics director John W. Childs sold 100,000 shares of common stock on August 12, 2026, through indirect holdings. These sales were conducted via the John W. Childs 2013 Revocable Trust and J.W. Childs Associates (FL), L.P., at weighted-average prices ranging from $106.14 to $108.24 per share. The transactions were reported on a Form 4 SEC filing, indicating a very negative sentiment and a high filing impact.

Published

14 Aug 2026 23:12

Catalyst

Market update

Coverage

Direct company

Duplicates

1 consolidated

Published

14 Aug 2026 12:29

Catalyst

Market update

Coverage

Direct company

Duplicates

1 consolidated